Observational study finds doxycycline use linked to 40-54% increased risk of pregnancy loss — Evidence Review
Published in Annals of Internal Medicine, by researchers from University of Florida
Researched by
— the AI search engine for science
Table of Contents
Taking doxycycline during the first trimester of pregnancy was linked to a moderately increased risk of pregnancy loss in a large new study. Related research on antibiotics in pregnancy shows mixed results, but several studies support an association between tetracycline-class antibiotics (including doxycycline) and higher miscarriage risk, though some earlier reviews found minimal teratogenic risk (original source).
- Multiple large observational studies and meta-analyses have reported that tetracyclines, including doxycycline, are associated with a higher risk of spontaneous miscarriage when used in early pregnancy, aligning with the new study's findings 2 3 4.
- Earlier systematic reviews suggested doxycycline may be safer than older tetracyclines regarding birth defects, but more recent analyses highlight increased risks of miscarriage and some congenital anomalies, indicating evolving evidence 1 2 5.
- Guidelines for antibiotic use in pregnancy increasingly emphasize caution with tetracyclines and recommend alternative agents for most infections, except when benefits outweigh risks 6 9 13.
Study Overview and Key Findings
The safety of antibiotic use in pregnancy has long been debated, particularly for broad-spectrum agents like doxycycline that are commonly prescribed for infections and acne. While previous guidance has focused on avoiding doxycycline in later pregnancy due to potential effects on fetal bone development, evidence regarding its safety in the first trimester has been inconsistent. This new study offers a large-scale, data-driven assessment of early pregnancy doxycycline exposure, providing important information on its association with pregnancy loss compared to alternative antibiotics.
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | University of Florida |
| Journal Name | Annals of Internal Medicine |
| Authors | Winterstein, A. G., Chen, H., Thai, T., Wang, Y., Smolinski, N. E., Wen, W., Ewig, C. L., Gilboa, S. M., Meaney-Delman, D., Maro, J. C., Rasmussen, S. A. |
| Population | Pregnant women ages 12 to 55 |
| Sample Size | n=224,870 |
| Methods | Observational Study |
| Outcome | Risk of pregnancy loss associated with doxycycline use |
| Results | Doxycycline users had a 40% to 54% higher risk of pregnancy loss. |
Literature Review: Related Studies
To evaluate how these findings fit within the broader research landscape, we searched the Consensus paper database, which includes over 200 million research papers. The following search queries were used to identify relevant studies:
- doxycycline pregnancy loss risk
- antibiotics effects on pregnancy outcomes
- acne treatment pregnancy complications
| Topic | Key Findings |
|---|---|
| How do tetracyclines and doxycycline affect pregnancy loss and birth outcomes? | - Tetracyclines (including doxycycline) are associated with a significantly increased risk of spontaneous miscarriage in several large studies and meta-analyses, particularly when used in early pregnancy 2 3 4. - Some reviews found minimal teratogenic risk from doxycycline exposure, especially compared to older tetracyclines, but recent evidence suggests specific risks of miscarriage and certain malformations 1 2 5. |
| Are alternative antibiotics safer in pregnancy, especially for acne or infections? | - Beta-lactams (penicillins, cephalosporins), macrolides (erythromycin, azithromycin), and clindamycin are generally considered safer alternatives for treating infections or acne during pregnancy 6 10 11 13 14. - Oral retinoids and tetracyclines are contraindicated in pregnancy due to established teratogenicity and risk of adverse outcomes 10 11 13 14. |
| What is the overall risk-benefit of treating infections (including acne) in pregnancy? | - Untreated maternal infections (e.g., respiratory, sexually transmitted) themselves increase risks of miscarriage, preterm birth, and low birth weight; effective antibiotic treatment can improve pregnancy outcomes 7 8. - Antibiotic use in pregnancy must balance infection risks against possible drug-related adverse outcomes, emphasizing individualized risk assessment and drug selection 6 8 9. |
How do tetracyclines and doxycycline affect pregnancy loss and birth outcomes?
The new study's association between first-trimester doxycycline use and increased pregnancy loss is consistent with several large observational studies and meta-analyses, which have reported elevated risks of spontaneous miscarriage and some congenital anomalies for tetracyclines and their derivatives. However, some earlier systematic reviews suggested doxycycline might have a safer profile than older tetracyclines, though more recent data point to miscarriage risk as a significant concern.
- Multiple meta-analyses and case-control studies confirm that tetracyclines, including doxycycline, are associated with a higher risk of spontaneous miscarriage when used during pregnancy, particularly in the first trimester 2 3 4.
- Some studies found a possible association between doxycycline and specific birth defects, such as cardiovascular malformations, although other analyses did not find consistent evidence of teratogenicity 2 5.
- A 2015 systematic review noted a lack of correlation between doxycycline and teratogenic effects or dental staining, distinguishing its safety profile from older tetracyclines, but called for more evidence-based evaluation 1.
- The magnitude of risk varies, but the evidence increasingly supports caution with tetracycline-class antibiotics in pregnancy, especially for non-severe infections 2 3 4.
Are alternative antibiotics safer in pregnancy, especially for acne or infections?
Current literature and clinical guidelines recommend several alternative antibiotics with better-established safety profiles for use during pregnancy. These include beta-lactams, macrolides, and clindamycin, which are preferred over tetracyclines and retinoids for treating infections and acne in pregnant patients.
- Oral retinoids (e.g., isotretinoin) and tetracyclines are contraindicated in pregnancy due to well-documented teratogenicity and risk of fetal toxicity 10 11 13 14.
- Beta-lactams and macrolides are generally considered safe and effective for treating acne or infections during pregnancy, with multiple studies and reviews supporting their use as first- or second-line agents 6 10 11 13 14.
- Guidelines emphasize the use of topical therapies as initial treatment for mild acne in pregnancy and recommend systemic antibiotics only for moderate-to-severe cases, with careful attention to trimester and individual risk 11 13 14.
- Clindamycin is widely used as an alternative in acne management during pregnancy when oral therapy is indicated 10 11.
What is the overall risk-benefit of treating infections (including acne) in pregnancy?
While some antibiotics carry risks, untreated infections themselves can contribute to adverse pregnancy outcomes, such as miscarriage, preterm birth, and stillbirth. The literature highlights the importance of individualized treatment decisions that weigh the risks of untreated infection against the potential adverse effects of specific antibiotics.
- Several studies demonstrate that timely and appropriate antibiotic treatment of infections like syphilis and chlamydia in pregnancy significantly reduces the risk of preterm birth, stillbirth, and low birth weight 7 8.
- Meta-analyses indicate that antibiotic prophylaxis can reduce postpartum infection risks and certain adverse outcomes, although benefits do not extend to all endpoints (e.g., preterm delivery) 7.
- Reviews and guidelines stress that antibiotic choice should be guided by infection severity, gestational age, and available safety data, avoiding agents with known fetal toxicity when possible 6 8 9.
- Many antibiotics have been insufficiently studied in pregnancy, underscoring the need for ongoing research and updated evidence-based recommendations 6 9.
Future Research Questions
Despite progress in understanding the safety of antibiotics during pregnancy, important gaps remain. Further research is needed to clarify causal mechanisms, evaluate trimester-specific risks, and inform safer prescribing practices.
| Research Question | Relevance |
|---|---|
| What mechanisms explain the association between doxycycline and pregnancy loss? | Determining the biological pathways could clarify causality and guide drug safety recommendations; current evidence is largely observational and mechanistic data are limited 2 3. |
| Does the timing or duration of doxycycline exposure impact pregnancy outcomes? | Understanding trimester-specific or exposure-dependent risks will inform safer prescribing and help identify critical windows of susceptibility 3 4. |
| How do confounding factors (such as infection severity) affect the observed association between antibiotic use and pregnancy loss? | Differentiating effects of the antibiotic from those of the underlying infection is crucial for interpreting risk estimates and informing clinical decisions 2 7 8. |
| What are the comparative safety profiles of newer antibiotics in pregnancy relative to doxycycline? | As new antibiotics are introduced, comparative studies are needed to evaluate risks and guide optimal choices for pregnant patients 9. |
| How can clinical guidelines better incorporate evolving evidence on antibiotic safety in pregnancy? | Ensuring that practice guidelines reflect the latest research will help minimize harm and optimize outcomes for pregnant women and their infants 6 9 13. |